Kumar is a highly accomplished business development executive with an impressive record of success in both pharma and biotech settings.lol比赛投注的app是什么
Kumar has a broad cross-functional background in business development, licensing, R&D, new 产品介绍 planning, finance and strategy, and is an effective leader of multidisciplinary 团队s.
Kumar joined AstraZeneca in April 2012 as Vice President, Business Development and was appointed Vice President and Global Head of Business Development and Licensing, BioPharmaceuticals R&D in September 2019. Kumar was previously Chief Business Officer at Probiodrug AG, then a private venture funded German company developing novel treatment for Alzheimer’s and inflammatory diseases. Before this he was Vice President, Global Business Development at Wyeth Pharmaceuticals, where he headed up business development and licensing activities for pre-phase 2 opportunities for several therapeutic areas.
As recognition of his broad industry experience, Kumar joined the Board of Directors at Pulmotect Inc. in 2019, a clinical-stage biotechnology company developing an inhaled immunomodulatory agent.
At AstraZeneca, we believe that scientific innovation and great collaboration go hand in hand. We know that to deliver the next generation of medicines, we must continue to find ways to combine our own great science with the best science that is happening in universities, industry and research institutes around the world.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.